This “synthetic lethality” effect of PARP‐1 inhibition is effective in breast cancer with BRCA mutations, but not in breast cancer with wild‐type BRCA [9, 10] and is enlarged to cover cancer cells showing other HR protein deficiencies [11]. Here, PARP1 is linked to breast carcinoma.